Compare Johnson & Johnson (JNJ) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs KB Financial Group, Inc. — how do they compare? Johnson & Johnson trades at $260.19 (market cap $618.09B), while KB Financial Group, Inc. trades at $122.76 (market cap $42.62B). The key difference: Johnson & Johnson is far larger — about 14.5× KB Financial Group, Inc.'s market cap, and KB Financial Group, Inc. pays the higher dividend (2.71%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and KB Financial Group, Inc. for 33 Days on average.
| JNJ | KB | |
|---|---|---|
Market Cap | $618.09B | $42.62B |
Volume | 6,050,983 | 164,291 |
Sector | Health | Financials |
52-Week High | $278.43 | $132.88 |
52-Week Low | $186.00 | $77.50 |
Typical Hold Time | 129 Days | 33 Days |
Enterprise Value | $646.37B | $215.53T |
Dividend Yield | 2.09% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
KB Financial Group trades at $122.78, down 1.56% today, with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with consistent earnings beats, growing revenue from $21.23T to $22.37T projected for 2026, and improving profit margins reaching 28.09%. Recent analyst coverage shows 33% buy ratings with positive momentum commentary from multiple financial outlets.
The outlook remains positive given KB's attractive valuation at 9.68 P/E and 0.94 P/B, coupled with sustained earnings growth. Key risks include market volatility and the company's significant investment outflows. Analyst consensus leans neutral with 67% hold ratings, suggesting cautious optimism for this value-oriented financial stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
